



James Inglese, PhD
Principal Investigator

*Assay and Screening Strategies for Chemical Probe and Drug
Discovery*

Dr. James Inglese, Ph.D. directs the Laboratory of Assay Development and Screening Technology (ADST) within the National Center for Advancing Translational Sciences (NCATS) and is an Adjunct Investigator within the National Human Genome Research Institute (NHGRI). His laboratory explores strategies aimed at enabling the identification of novel chemical matter targeting the discovery of chemical probes and therapeutic leads for the study and treatment of rare and neglected disease. The NCATS post-doctoral training program he has established is recognized by disease foundations as an effective collaborative bridge to NCATS expertise and resources enabling a champion-driven effort in early-stage translation. Prior to the formation of NCATS he co-founded the NIH Chemical Genomics Center (NCGC) acting as its Deputy Director. Dr. Inglese received his Ph.D. in Organic Chemistry from the Pennsylvania State University and completed post-doctoral training in the laboratory of future 2012 Nobel Laureate Prof. Robert J. Lefkowitz at Duke University Medical Center. Before coming to the NIH, Dr. Inglese led research teams at the combinatorial chemistry Princeton-based biotech Pharmacopeia and Merck Research Laboratories. Over the past several decades, Dr. Inglese has contributed to over 180 publications and patents; his efforts on the early drug discovery process have resulted in innovative assay formats, reporter systems, and high throughput screening paradigms. Dr. Inglese serves on the scientific advisory boards of several NIH-funded chemistry and screening centers, disease foundations, and international chemical biology consortia.

Head Assay Development & Screening Technology (ADST)
National Center for Advancing Translational Sciences (NCATS), NIH